Adrenergic Receptor Polymorphisms and Prevention of Atrial Fibrillation with Bucindolol in Patients with Heart Failure
Sauer W., et. al.
Abstract AHA 2007

Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias with Bucindolol in Patients with Congestive Heart Failure
Sauer W., et. al.
Abstract AHA 2007

Effect of β1 389 Arg/Gly α2c 322-325 Wt/Del Genotypes on Adjudicated Hospitalizations in the BEST Trial
Carson, et. al.
Abstract AHA 2007

Effects of Bucindolol on Cardiovascular Mortality and Morbidity are Determined by the β1 389 Arg/Gly Receptor Polymorphism
White, et. al.
Abstract AHA 2007

Pharmacogenomic Applications in Heart Failure: Can Therapy be Improved by Targeting Genetic Sub-populations?
HFSA 2007 Symposium, CME Highlights

Pharmacogenetic therapeutic enhancement of a prespecified composite morbidity-mortality measurement in BEST
Zolty R., et. al.
Abstract HFSA 2007

Differential Effects of β-1 Polymorphisms on Mortality, Hospitalizations, and Myocardial Infarctions with Bucindolol Therapy
Lowes B., et. al.
Abstract HFSA 2006